WG
VNDA icon

Winton Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Winton Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Buy
+44,800
New +$345K 0.01% 854
2024
Q4 		– Sell
-72,465
Closed -$340K – 794
2024
Q3 		$340K Sell
72,465
-41,018
-36% -$220K 0.02% 498
2024
Q2 		$641K Sell
113,483
-50,343
-31% -$260K 0.04% 389
2024
Q1 		$673K Buy
163,826
+50,734
+45% +$203K 0.05% 428
2023
Q4 		$477K Buy
113,092
+25,599
+29% +$103K 0.03% 339
2023
Q3 		$378K Buy
87,493
+2,293
+3% +$12.7K 0.03% 433
2023
Q2 		$561K Buy
85,200
+19,331
+29% +$124K 0.05% 276
2023
Q1 		$447K Sell
65,869
-5,093
-7% -$35.8K 0.03% 729
2022
Q4 		$524K Buy
70,962
+17,585
+33% +$171K 0.03% 611
2022
Q3 		$527K Sell
53,377
-23,805
-31% -$251K 0.03% 628
2022
Q2 		$841K Buy
77,182
+59
+0.1% +$611 0.04% 536
2022
Q1 		$872K Buy
77,123
+20,101
+35% +$264K 0.05% 513
2021
Q4 		$895K Sell
57,022
-13,270
-19% -$231K 0.05% 499
2021
Q3 		$1.21M Sell
70,292
-11,286
-14% -$198K 0.07% 408
2021
Q2 		$1.75M Sell
81,578
-8,329
-9% -$149K 0.09% 236
2021
Q1 		$1.35M Sell
89,907
-9,050
-9% -$147K 0.08% 307
2020
Q4 		$1.3M Sell
98,957
-178,244
-64% -$2.15M 0.09% 278
2020
Q3 		$2.68M Sell
277,201
-308,047
-53% -$3.29M 0.09% 391
2020
Q2 		$6.7M Buy
585,248
+21,725
+4% +$246K 0.17% 121
2020
Q1 		$5.84M Buy
563,523
+10,883
+2% +$135K 0.15% 189
2019
Q4 		$9.07M Buy
552,640
+529,686
+2,308% +$8.01M 0.13% 269
2019
Q3 		$305K Buy
+22,954
New +$320K ﹤0.01% 1274

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winton Group's VNDA Position: Q1 2026 in Review

Winton Group opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2026: 44,800 shares worth $310K. The stake represents 0.01% of the portfolio and ranks #854 among its holdings. This is a return to the name: Winton Group previously reported a position in VNDA as recently as Q3 2024.

Winton Group first reported a position in VNDA in Q3 2019 and has held it in 22 quarters since. The position peaked at $9.07M in Q4 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Winton Group held 44,800 shares of Vanda Pharmaceuticals worth $310K as of Q1 2026.
  • Vanda Pharmaceuticals was a new Winton Group position in Q1 2026.
  • Vanda Pharmaceuticals made up 0.01% of Winton Group's portfolio in Q1 2026, its #854 holding.
  • Winton Group first reported a position in Vanda Pharmaceuticals in Q3 2019 and has held it in 22 quarters since.
  • Winton Group's Vanda Pharmaceuticals position peaked at $9.07M in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.